In order to stay ahead of the game, Pharma and Biotech companies are continuously innovating in their R&D programmes.
BiopharmaTrend.com recently listed an overview of the top 7 most influential research trends affecting the biopharmaceutical industry in 2018 and beyond; together with the key players driving innovations. We summarized these trends for you:
1. Artificial Intelligence (AI) finds its ways to the pharma and biotech sector
AI-driven companies really start getting traction with big pharma and other leading life science players.
A potential of AI-based tools is now being explored at all stages of drug discovery and development, such as:
- Research data mining;
- Target identification and validation;
- Planning chemical synthesis to obtain compounds of interest;
- Planning pre-clinical and clinical trials;
- Analyzing biomedical and clinical data;
2. Expanding chemical space for drug discovery explorations
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
A vital part of small molecule drug discovery is hit exploration: identifying the starting point molecules which would embark on a journey towards successful medications via numerous optimization, validation and testing stages.
The key element of hit exploration is the access to an expanded and chemically diverse space of drug like molecules to choose candidates from, especially, for probing novel target biology.
Academic labs and private companies are now creating chemical compound databases that are far beyond what is available in typical pharmaceutical company compound collections.
3. Targeting RNA with small molecules
A number of recent advances suggest that it is possible to develop drug-like, biologically active small molecules that target RNA.
4. New antibiotics discovery
Antibiotics discovery is becoming a more attractive area due to some beneficial changes in regulatory legislature, stimulating pharma to pour money into antibiotics discovery programs, and venture investors into biotech startups developing promising antibacterial medicines.
5. Phenotypic screening
During the past 5 years, considerably more of the first-in-class small molecule drugs have been discovered using phenotypic screening rather than target-based approaches.
6. Organs (body)-on-a-chip: an alternative to animal testing?
Microchips lined by living human cells could revolutionize drug development, disease modelling and personalized medicine. These microchips, called ‘organs-on-chips’, offer a potential alternative to traditional animal testing.
7. Bioprinting: the future of medicine
The area of bioprinting human tissues and organs is rapidly evolving and is, undoubtedly, the future of medicine.
These are just some of the trends. They all illustrate that pharmaceutical companies should continue to engage in R&D outsourcing models – in order to gain access to external innovations and expertise.
Date: August 14, 2018
Source: cmast
